News
The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...
Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback